FDA Grants Orphan Drug Designation to NeoImmuneTech's NT-I7 for the Treatment of Acute Radiation Syndrome

The FDA's Orphan Drug Designation is aimed at advancing treatments for rare diseases, including Acute Radiation Syndrome (ARS), which currently has limited treatment options NeoImmuneTech's NT-I7 has shown potential in nonclinical studies to address the... Biopharmaceuticals, FDA NeoImmuneTech, efineptakin alfa, Acute Radiation Syndrome
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news